AR054050A1 - Derivados de piperidina para el tratamiento de enfermedades mediadas por quimioquinas,composiciones farmaceuticas que los contienen y metodo de preparacion de los mismos - Google Patents
Derivados de piperidina para el tratamiento de enfermedades mediadas por quimioquinas,composiciones farmaceuticas que los contienen y metodo de preparacion de los mismosInfo
- Publication number
- AR054050A1 AR054050A1 ARP060102206A ARP060102206A AR054050A1 AR 054050 A1 AR054050 A1 AR 054050A1 AR P060102206 A ARP060102206 A AR P060102206A AR P060102206 A ARP060102206 A AR P060102206A AR 054050 A1 AR054050 A1 AR 054050A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- chemiokines
- piperidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) donde R1 es fenilo opcionalmente sustituido con halogeno, ciano, C1-4 alquilo o C1-4 alcoxi; R2 es H o hidroxi; R3 es H, C1-6 alquilo o fenil(C1-4 alquilo); donde fenilo está opcionalmente sustituido con halogeno, hidroxi, nitro, S(O)q(C1-4 alquilo), S(O)2NH2, S(O)2NH(C1-4 alquilo), S(O)2N(C1-4 alquil)2, ciano, C1-4 alquilo, C1-4 alcoxi, C(O)NH2, C(O)NH(C1-4 alquilo), C(O)N(C1-4 alquil)2, CO2H, CO2(C1-4 alquilo), NHC(O)(C1-4 alquilo), NHS(O)2(C1-4 alquilo), C(O)(C1-4alquilo), CF3 o OCF3; q es 0, 1 o 2; R4 es metilo, CH(CH3)2, o 3-7 cicloalquilo opcionalmente sustituido con C1-4 alquilo; R5, R6 y R7 son, en forma independiente entre sí, H o metilo; o R4 y R5 se unen para formar un anillo carbocíclico de entre 3 y 7 miembros opcionalmente sustituido con C1-4 alquilo; y dos de los C del anillo de este anillo pueden estar unidos a través de una cadena alquileno de 1 o 2 C (que a su vez está opcionalmente sustituida con C1-4 alquilo) de manera de formar un sistema de anillos bicíclico, o un N-oxido del mismo, o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501212 | 2005-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054050A1 true AR054050A1 (es) | 2007-05-30 |
Family
ID=37452280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102206A AR054050A1 (es) | 2005-05-27 | 2006-05-26 | Derivados de piperidina para el tratamiento de enfermedades mediadas por quimioquinas,composiciones farmaceuticas que los contienen y metodo de preparacion de los mismos |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080275084A1 (es) |
| EP (1) | EP1888526A1 (es) |
| AR (1) | AR054050A1 (es) |
| TW (1) | TW200722419A (es) |
| WO (1) | WO2006126947A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| ES2397418T3 (es) | 2005-07-21 | 2013-03-06 | Astrazeneca Ab | Derivados de piperidina |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588722A (en) * | 1984-01-09 | 1986-05-13 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives |
| US4695575A (en) * | 1984-11-13 | 1987-09-22 | Janssen Pharmaceutica, N.V. | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5952349A (en) * | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| TR199900314T2 (xx) * | 1996-08-15 | 1999-05-21 | Schering Corporation | Eter muskarinik antagonistleri. |
| US5977138A (en) * | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| TWI245763B (en) * | 1998-04-02 | 2005-12-21 | Janssen Pharmaceutica Nv | Biocidal benzylbiphenyl derivatives |
| US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| TW474933B (en) * | 1998-06-30 | 2002-02-01 | Schering Corp | Muscarinic antagonists |
| EP1140834A1 (en) * | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| US6294554B1 (en) * | 1999-09-22 | 2001-09-25 | Schering Corporation | Muscarinic antagonists |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| AU2002244271A1 (en) * | 2001-03-13 | 2002-09-24 | Pharmacopeia, Inc. | Non-imidazole compounds as histamine h3 antagonists |
| ATE319703T1 (de) * | 2001-07-02 | 2006-03-15 | Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen | |
| GB0117899D0 (en) * | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| GB0120461D0 (en) * | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| SE0200844D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US6696468B2 (en) * | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300850D0 (sv) * | 2003-03-25 | 2003-03-25 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) * | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0301368D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
-
2006
- 2006-05-22 TW TW095118093A patent/TW200722419A/zh unknown
- 2006-05-24 WO PCT/SE2006/000611 patent/WO2006126947A1/en active Application Filing
- 2006-05-24 US US11/915,460 patent/US20080275084A1/en not_active Abandoned
- 2006-05-24 EP EP06747805A patent/EP1888526A1/en not_active Withdrawn
- 2006-05-26 AR ARP060102206A patent/AR054050A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006126947A1 (en) | 2006-11-30 |
| TW200722419A (en) | 2007-06-16 |
| EP1888526A1 (en) | 2008-02-20 |
| US20080275084A1 (en) | 2008-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR109033A2 (es) | Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR057688A1 (es) | CARBOXAMIDAS HETEROCíCLICAS Y SU USO EN COMPOSICIONES FUNGICIDAS. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR057244A1 (es) | Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes. | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR061374A1 (es) | Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos | |
| CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR041066A1 (es) | 2,5-dioxoimidazolidin-4-il-acetamidas y analogos como inhibidores de la metaloproteinasa mmp12 | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |